What should you know about FLI1 immunohistochemistry?

A pathologist applies an antibody designed to bind FLI1 to prepared tissue. A visible signal may be described by its location in the cell, its strength, and the proportion of cells showing it. The report may use terms such as positive, negative, weak, strong, focal, or diffuse. Those words describe the stain pattern, not the entire diagnosis.

FLI1 staining can support the distinction between tumour types, but it is not interpreted alone. The pathologist combines it with the tissue appearance, the biopsy site, clinical information, and other stains or molecular tests when needed. A positive result does not automatically prove one specific cancer, and a negative result does not settle every diagnostic question.

Request the complete pathology report and ask which cells were stained and what comparison tests were used. Ask whether the sample was large enough and well preserved for interpretation. If the wording is uncertain, your treating clinician may discuss the case with the pathologist or request additional testing. Keep the report with your imaging and biopsy information so results are considered together.

FLI1 staining itself does not cause symptoms and is not an emergency result. Contact your clinical team if you have not received an explanation of a pathology finding, if a planned appointment has been missed, or if you develop new or worsening symptoms after the biopsy, such as increasing redness, swelling, drainage, fever, or bleeding. Urgent care is appropriate for severe bleeding, fainting, or breathing difficulty.

Ask what FLI1 means in your specific sample, whether the staining is focal or diffuse, which alternative diagnoses were considered, whether more stains are needed, and how the result changes the next diagnostic or treatment step.